Molecular insight in cancer treatment and prevention

International Journal of Biochemistry and Cell Biology

Volumn 39, Issue 7-8, 2007, Pages 1329-1336

  Balducci, Lodovico ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Cancer; Molecular insights; Prevention; Targeted therapy; Treatment

Indexed keywords

ALEMTUZUMAB; AZACITIDINE; BEVACIZUMAB; BORTEZOMIB; CAPECITABINE; CETUXIMAB; ERLOTINIB; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; LAPATINIB; LENALIDOMIDE; PANITUMUMAB; RITUXIMAB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; THALIDOMIDE; TIPIFARNIB; TOSITUMOMAB;

ACNE; BONE MARROW SUPPRESSION; CANCER; CANCER PREVENTION; CANCER THERAPY; CORONARY ARTERY DISEASE; DEEP VEIN THROMBOSIS; GENOMICS; HUMAN; HYPERTENSION; KIDNEY DISEASE; PROTEINURIA; SHORT SURVEY; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 34447100265     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biocel.2007.03.005     Document Type: Short Survey

References (62)

1. Ajani J. Review of capecitabine as oral treatment of gastric, gastro-esophageal, and esophageal cancers. Cancer 107 2 (2006 Jul 15) 221-231
2. Baglole C.J., Ray D.M., Bernstein S.H., et al. More than structural cells, fibroblasts create and orchestrate the tumor microenvironment. Immunol. Invest. 35 3/4 (2006) 297-325
3. Bedikian A.Y., Millward M., Pehamberger H., et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: The Oblimersen Melanoma Study Group. J. Clin. Oncol. 24 29 (2006 Oct 10) 4738-4745
4. Belinky S.A., Kliman D.M., Decker J.D., et al. Gene promoter methylation in plasma and sputum increases with lung cancer risk. Clin. Cancer Res. 11 (2005 Sep 15) 6505-6511
5. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 354 6 (2006 Feb 9) 567-578
6. Burt R., and Neklason W.E. Genetic testing for inherited colon cancer. Gastroenterology 128 6 (2005 May) 1696-1716
7. Cavo M. Proteasome inhibitor bortezomib for the treatment of multiple myeloma. Leukemia 20 8 (2006 Aug) 1341-1352
8. Coiffier B. Standard treatment of advanced-stage diffuse large B-cell lymphoma. Semin. Hematol. 43 4 (2006 Oct) 213-220
9. Dearden C. The role of alemtuzumab in the management of T-cell malignancies. Semin. Oncol. 33 2 Suppl. 5 (2006 Apr) S44-S52
10. DeVisser K.E., and Coussens L.M. The inflammatory tumor microenvironment and its impact on cancer development. Contrib. Microbiol. 13 (2006) 118-137 [Review]
11. Easton J.B., and Houghton P.J. mTOR and cancer therapy. Oncogene 25 48 (2006 Oct 16) 6436-6446
12. Faivre S., Djelloul S., and Raymond E. New paradigms in anticancer therapy: Targeting multiple signaling pathways with kinase inhibitors. Semin. Oncol. 33 4 (2006 Aug) 407-420 [Review]
13. Fan C., Oh D.S., Wessels L., et al. Concordance among gene-expression-based predictors for breast cancer. N. Engl. J. Med. 355 6 (2006 Aug 10) 560-569
14. Gollob J.A., Wilhelm S., Carter C., et al. Role of Raf kinase in cancer: Therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin. Oncol. 33 4 (2006 Aug) 392-406 [Review]
15. Gonzalez-Angulo A.M., Hortobagyi G.N., and Esteva F.J. Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer. Oncologist 11 8 (2006 Sep) 857-867
16. Gore S.D. Six (or more) drugs in search of a mechanism: DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes. J. Natl. Compr. Canc. Netw. 4 1 (2006 Jan) 83-90
17. Haluska J., Dy J.K., and Adjiei A.A. Farnesyl transferase inhibitors as anticancer agents. Eur. J. Cancer 38 13 (2002 Sep) 1685-1700
18. Henke M., Mattern D., Pepe M., et al. Do erythropoietin receptors on cancer cells explain unexpected clinical findings?. J. Clin. Oncol. 24 (2006) 4708-4713
19. Hirano T., and Kato H. Present status of clinical proteomic analysis for the early detection and determination of therapeutic strategy in lung cancer. Ann. Thorac. Cardiovasc. Surg. 12 1 (2006 Feb) 4-9
20. Hirch F.R., Varella Garcia M., Bunn P., et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J. Clin. Oncol. 24 31 (2006 Nov 1) 5034-5042
21. Hurwitz H., Fehrerbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350 23 (2004 Jun 3) 2335-2342
22. Johnson D.H., Fehrenbacher L., Novotny W.F., et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol. 22 11 (2004 Jun 1) 2184-2191
23. Johnson L.R., and Leary A. Lapatinib: A novel EGFR/HER2 tyrosine kinase inhibitor for cancer. Drugs Today (Barc) 42 7 (2006 Jul) 441-453 [Review]
24. Kaminski M.S., Tuck M., Estes J., et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N. Engl. J. Med. 352 (2005) 441-449
25. Kumasheva R.T., and Houghton P.J. IGF-I mediated survival pathways in normal and malignant cells. Biochim. Biophys. Acta 1766 1 (2006 Aug) 1-22
26. Larson R.A., Sievers E.L., Stadtmauer E.A., et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 104 7 (2005 Oct 1) 1442-1452
27. List A., Dewald G., Bennett J., et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N. Engl. J. Med. 355 14 (2006 Oct 5) 1456-1465
28. Liu O., Fayad L., Cabanillas F., et al. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J. Clin. Oncol. 24 10 (2006 Apr 1) 1582-1589
29. Macklis R.M., and Pohlman B. Radioimmunotherapy for non-Hodgkin's lymphoma: A review for radiation oncologists. Int. J. Radiat. Oncol. Biol. Phys. 66 3 (2006 Nov 1) 833-841
30. Monneret C. Histone deacetylase inhibitors for epigenetic therapy of cancer. Anticancer Drug 18 (2007) 363-370
31. Moore M.G. Brief communication: A new combination in the treatment of advanced pancreatic cancer. Semin. Oncol. 32 6 Suppl. 8 (2005 Dec) 5-6
32. Morris P.J., and Russell N.K. Alemtuzumab (Campath-1H): A systematic review in organ transplantation. Transplantation 81 10 (2006 May 27) 1361-1367 [Review]
33. Motzer R.J., Rini B.I., and Bukowski R.M. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295 21 (2006 Jun 7) 2516-2524
34. Nabeshima K., Iwasaki H., Koga K., et al. Emmprin (basigin/CD147): Matrix metalloproteinase modulator and multifunctional cell recognition molecule that plays a critical role in cancer progression. Pathol. Int. 56 7 (2006 Jul) 359-367
35. Nalepa G., Rolfe M., and Harper A.G. Drug discovery in the ubiquitin-proteasome system. Nat. Rev. Drug Discov. 5 7 (2006 Jul) 596-613
36. Nelson H., Huffman L.H., Fu R., et al. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: Systematic evidence review for the U.S. Preventive Services Task Force. Ann. Intern. Med. 143 5 (2005 Sep 6) 362-379
37. Ng R., Better N., and Green M.D. Anticancer agents and cardiotoxicity. Semin. Oncol. 33 1 (2006 Feb) 2-14
38. O'Dweir P.J. The present and future of angiogenesis-directed treatments of colorectal cancer. Oncologist 11 9 (2006 Oct) 992-998
39. Ohno R. Treatment of chronic myeloid leukemia with imatinib mesylate. Int. J. Clin. Oncol. 11 3 (2006 Jun) 176-183
40. Olaussen K.A., Dounant A., Fouret P., et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N. Engl. J. Med. 355 10 (2006 Sep 7) 983-991
41. Perez-Tomas R. Multidrug resistance: Retrospect and prospects in anti-cancer drug treatment. Curr. Med. Chem. 13 16 (2006) 1859-1876
42. Plosker G.L., and Kim L.J. Trastuzumab: A review of its use in the management of HER2-positive metastatic and early-stage breast cancer. Drugs 66 4 (2006) 449-475
43. Potter P.M., and Wadkins A.M. Carboxylesterases-detoxifying enzymes and targets for drug therapy. Curr. Med. Chem. 13 9 (2006) 1045-1054 [Review]
44. Rai K.H. Novel therapeutic strategies with alemtuzumab for chronic lymphocytic leukemia. Semin. Oncol. 33 2 Suppl. 5 (2006 Apr) S15-S22
45. Ramaswami B., Elias A.D., Kelbick N.T., et al. Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients. Clin. Cancer Res. 12 10 (2006 May 15) 3124-3129
46. Ratain M.J., Eisen T., Stadler W.M., et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 24 16 (2006 Jun 1) 2505-2512
47. Realacci M., Perrone G.A., Sale P., et al. Detection of oncogenic HPV and identification of 72Arg polymorphic p53 by in situ PCR for clinical routine purposes. Anticancer Res. 26 4B (2006 Jul-Aug) 3095-3103
48. Rhee J., Oishi K., Garey J., et al. Management of rash and other toxicities in patients treated with epidermal growth factor receptor-targeted agents. Clin. Colorectal Cancer. 5 Suppl. 2 (2005 Nov) S101-S106
49. Richardson P.G., Mitsiades C., Hideshima T., et al. Lenalidomide in multiple myeloma. Expert Rev. Anticancer Ther. 6 8 (2006 Aug) 1165-1173
50. Rubio-Viquiera D., and Hidalgo M. Targeting mTOR for cancer treatment. Curr. Opin. Investig. Drugs 7 6 (2006 Jun) 501-512
51. Sang Q.X., Jin Y., Newcomer P.G., et al. Matrix metalloproteinase inhibitors as prospective agents for the prevention and treatment of cardiovascular and neoplastic diseases. Curr. Top. Med. Chem. 6 4 (2006) 289-316
52. Schilder R., Molina A., Bartlett N., et al. Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia. Cancer Biother. Radiopharm. 19 4 (2004 Aug) 478-481
53. Schrag D., Chang K.Y., and Flombaum C. Cetuximab therapy and symptomatic hypomagnesemia. J. Natl. Cancer Inst. 97 (2005) 1221-1224
54. Talpaz M., Shah N.P., Kantarjan H., et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 354 24 (2006 Jun 15) 2531-2541
55. Tsao M.S., Sakurada C., Cutz J.C., et al. Erlotinib in lung cancer-Molecular and clinical predictors of outcome. N. Engl. J. Med. 353 2 (2005 Jul 14) 133-144
56. Van Cutsem. Challenges in the use of epidermal growth factor receptor inhibitors in colorectal cancer. Oncologist 11 9 (2006 Oct) 1010-1017 [Review]
57. Vokes E.E., and Chu E. Anti-EGFR therapies: Clinical experience in colorectal, lung, and head and neck cancers. Oncology (Williston Park) 20 5 Suppl. 2 (2006 Apr) 15-25
58. Wang W., McLeod H.L., Cassidy J., et al. Mechanisms of acquired chemoresistance to 5-fluorouracil and tomudex: Thymidylate synthase dependent and independent networks. Cancer Chemother. Pharmacol. (2006 Nov 22) [Epub ahead of print]
59. Wilson R.H. Novel therapeutic developments other than EGFR and VEGF inhibition in colorectal cancer. Oncologist 11 9 (2006 Oct) 1018-1024
60. Yang G.C., Haworth L., Sherry A.M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 349 5 (2003 Jul 31) 427-433
61. Yashwanth R., Rama S., Ambalagan N., et al. Role of estrogen in regulation of cellular differentiation: A study using human placental and rat Leydig cells. Mol. Cell Endocrinol. 246 1/2 (2006 Feb 26) 114-120
62. Zimmerman T.M., Harlin H., Odenike O.M., et al. Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies. J. Clin. Oncol. 22 23 (2004 Dec 1) 4816-4822